Industries > Pharma > Biomarkers: Technological and Commercial Outlook 2013-2023
Biomarkers: Technological and Commercial Outlook 2013-2023
Biomarkers – how to find R&D trends and potential sales
What’s the outlook for biomarkers? Visiongain’s updated report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.
That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. See what’s happening for those technologies, finding how you can gain.
Read on, then, to explore that industry and see what its future market could be worth.
Forecasts 2013-2023 and other analyses show you commercial prospects
Besides revenue forecasting, our work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 65 tables, 60 charts, and two interviews.
Is your searching for data on biomarkers a challenging task? Now make it easier. You can stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.
Our new study lets you investigate the most promising and lucrative parts of that field – assess technologies and their applications. You hear what’s happening and see where the money lies. Try our new report, then, getting a feel for that industry’s potential.
The following sections show how you benefit from our investigation.
Prospects for the world biomarkers market and its submarkets
Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of 11 biomarker submarkets to 2023, starting with main divisions:
You see, too, world revenues to 2023 divided into technological disciplines:
• Other applications.
You also find world revenue predictions to 2023 by therapeutic field:
• Cardiovascular diseases
• CNS disorders
• Other illnesses.
How will those markets for biomarkers expand? Which applications will generate most money? You investigate that industry, finding the most promising places for investments and sales.
The study also breaks its overall forecast into geographical regions.
National markets – what outlooks for biomarker demand?
Worldwide progress in pharmaceuticals and diagnostics expand use of biomarkers. Hear about the best revenue prospects for those medical tools.
Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC).
There you discover countries with highest revenues and potential sales growth. Our work explains. You assess that technology’s future, seeing progress and finding what it means.
Developments and opportunities affecting biomarkers
Our report shows you issues and events affecting that industry and market from 2013, including these:
• Biomarkers for efficacy and safety of drugs
• Companion diagnostics and personalised medicines
• Imaging biomarkers in clinical trials
• Pharmacogenomics, proteomics, and metabolomics.
That study discusses other aspects of the technology too, including these:
• Funding for biomarker discovery and research
• Validation of biomarkers in oncology
• Mergers and acquisitions (M&A)
• Alliances, partnerships, collaborations, and licensing
• Interest from pharma companies, inc. Pfizer, Novartis, Merck, Sanofi, and Roche.
There you explore political, economic, social, and technological questions, assessing outlooks for business. See, then, what restrains and what helps the biomarkers industry.
You investigate R&D too, finding possibilities for technological and commercial advances. See there what the future holds.
Companies and 2018 market value
What happens next? Our report predicts the world market for biomarker systems will reach $29.25bn in 2018 – with high growth – and expand further to 2023. Find how high revenues can go.
Our work also shows you what technologies and organisations hold greatest potential. See profiles of 25 companies. First you examine contract service providers (CROs), including these:
• Charles River Laboratories
• WuXi AppTec.
Next you assess technology providers, including these companies:
• Life Technologies
• Thermo Fisher Scientific.
Then, for diagnostic testing systems, you examine developers and producers including these:
• Quest Diagnostics
• Myriad Genetics
• Genomic Health
• Critical Diagnostics
There you analyse participants’ results, capabilities, and outlooks. You find 210 organisations mentioned. You also read two interviews with leaders in the industry. Discover what authorities think, say, and do, helping you stay ahead.
Information found nowhere else
Biomarkers: Technological and Commercial Outlook 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.
With that report you are less likely to fall behind in knowledge or miss sales opportunity. See how you could benefit your research, analysis, and decisions. Also find how you can save time and get recognition for insight.
Biomarkers for healthcare – assess potentials now, seeing what you can gain
Our new report is for everyone investigating biomarker technologies. There discover revenue forecasts to 2023 at overall world market, submarket, and national level. Find discussions too. Avoid missing out then – please order the report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here